This excerpt taken from the ACAD 8-K filed Sep 13, 2005.
Item 1.01 Entry Into a Material Definitive Agreement
On September 9, 2005, our Board of Directors approved an updated compensation program for the non-employee directors as set forth in Exhibit 99.1 hereto.
In addition, the Board of Directors approved a one-time grant of an option to purchase 8,500 shares of our common stock to each of the non-employee directors who were continuing in office as of September 9, 2005. The strike price for such grants were set at the fair market value for our common stock in accordance with the terms of our 2004 Equity Incentive Plan.
This excerpt taken from the ACAD 8-K filed Apr 20, 2005.
Item 1.01 Entry into a Material Definitive Agreement.
On April 15, 2005 ACADIA Pharmaceuticals Inc., a Delaware corporation (ACADIA), entered into a Securities Purchase Agreement with the purchasers set forth on Exhibit A thereto (the Securities Purchase Agreement), pursuant to which ACADIA sold, at the closing on April 20, 2005, at a price of $6.82125 per share, 5,277,621 shares of its common stock (the Shares) and warrants to purchase 1,319,402 shares of its common stock (the Warrants) with an exercise price of $8.148 per share (the Private Placement). The Warrants become exercisable 180 days after the closing of the Private Placement and expire on April 19, 2010, unless earlier terminated. Under the terms of the Securities Purchase Agreement, ACADIA has agreed to file, within 30 days after the closing of the Private Placement, a registration statement with the Securities and Exchange Commission to register for resale the Shares and the shares of common stock issuable upon the exercise of the Warrants, which registration statement is required under the Securities Purchase Agreement to become effective within 105 days following the closing.
The following purchasers were, individually or with their affiliates, holders of more than 5% of ACADIAs outstanding capital stock as of immediately prior to the closing of the sale: Oxford Bioscience Partners IV, L.P., and its affiliated funds including mRNA Fund II L.P. Additionally, the following members of ACADIAs board of directors have relationships with certain purchasers in the Private Placement as follows: (i) Carl Gordon is a general partner of OrbiMed Advisors LLC, which provides investment advisory services to Finsbury Worldwide Pharmaceutical Trust, (ii) Martien van Osch is Vice President of ABN AMRO Capital, a company affiliated with ABN AMRO Ventures BV, both of which are majority owned by ABN AMRO NV, and (iii) Alan Walton is a general partner of OBP Management IV L.P., the general partner of Oxford Bioscience Partners IV, L.P.
The foregoing is a summary of the terms of the Securities Purchase Agreement and does not purport to be complete and is qualified in its entirety by reference to the full text of the Securities Purchase Agreement, a copy of which is attached hereto as Exhibit 99.1.
This excerpt taken from the ACAD 8-K filed Jan 14, 2005.
Item 1.01 Entry into a Material Definitive Agreement.
On January 10, 2005 (the Effective Date), ACADIA Pharmaceuticals Inc. (ACADIA) entered into a License, Option and Collaboration Agreement (Collaboration Agreement) with Sepracor Inc. (Sepracor) for the development of new drug candidates targeted towards the treatment of central nervous system disorders. The collaboration has been established to investigate potential clinical candidates resulting from using ACADIAs medicinal chemistry and discovery platform against a broad array of selective muscarinic receptors, which are receptors that respond to acetylcholine, a neurotransmitter in the central nervous system. The collaboration includes ACADIAs m1 agonist program, which would target neuropsychiatric/neurologic conditions and neuropathic pain. Under the Collaboration Agreement, the parties have agreed to collaborate with each other to research and develop certain compounds that interact with these muscarinic receptors. These compounds may be developed and commercialized in any field outside of the prevention or treatment of ocular disease. Sepracor will have exclusive worldwide rights to develop and commercialize these compounds.
Under the Collaboration Agreement, ACADIA has also granted to Sepracor an option to select and obtain exclusive worldwide rights to develop and commercialize one preclinical compound from ACADIAs 5-HT2A program for use in combination with LUNESTA (eszopiclone), Sepracors insomnia drug, for sleep-related indications. To exercise this option, Sepracor is required to pay ACADIA an option exercise fee prior to the end of a specified option exercise period. ACADIAs Phase II programs encompassing ACP-103 for treatment-induced dysfunction in Parkinsons disease, ACP-103 as an adjunctive therapy for schizophrenia, and ACP-104 for treatment of schizophrenia, are not included as part of the collaboration.
During the three-year research term of the Collaboration Agreement, Sepracor will provide ACADIA with research funding. In addition, Sepracor has agreed to pay ACADIA milestone payments upon the achievement of specified development and regulatory milestones for each product developed under the collaboration, including any combination product with LUNESTA that is developed under the collaboration. Sepracor has also agreed to pay ACADIA royalties on net worldwide sales on products developed under the collaboration. If all development and regulatory milestones are achieved with respect to a single product in the muscarinic program, Sepracor would be required to pay ACADIA up to approximately $40 million in aggregate milestone and research funding payments in addition to royalties on net worldwide sales of such product. If all development and regulatory milestones are achieved with respect to any combination product with LUNESTA for sleep-related indications, Sepracor would be required to pay ACADIA up to approximately $35 million in aggregate milestone and option exercise payments in addition to royalties on net worldwide sales of such product.
The Collaboration Agreement will expire once Sepracors obligation to pay royalties to ACADIA under the Collaboration Agreement has terminated, provided that at least one
muscarinic compound has been selected by Sepracor by the end of the three-year research term or the 5-HT2A option has been exercised by Sepracor. If no muscarinic compound has been selected by the end of the three-year research term and the 5-HT2A option has not been exercised, then the Collaboration Agreement will expire immediately following the end of the three-year research term. Either party may terminate the Collaboration Agreement for cause by giving advance written notice to the other party of an uncured material breach by the other party or of the bankruptcy, insolvency, dissolution or winding up of the other party. Sepracor has the right to terminate the Collaboration Agreement for any reason after the expiration of the research term by giving advance written notice to ACADIA. ACADIA has the right to terminate the Collaboration Agreement if Sepracor does not purchase the shares of ACADIA common stock that it is required to purchase on the one year anniversary of the Effective Date pursuant to the stock purchase agreement described below. A copy of the Collaboration Agreement is filed as Exhibit 99.1 to this current report, the contents of which are incorporated herein by reference.
In connection with the collaboration, Sepracor has agreed to purchase up to an aggregate of $20 million of ACADIA common stock in two tranches pursuant to the terms of a stock purchase agreement. In the first tranche, which closed on January 13, 2005, Sepracor purchased $10 million of ACADIA common stock at a 40 percent premium to the average closing sales price for the 30 trading days prior to the Effective Date. ACADIA issued 1,077,029 shares of its common stock to Sepracor in the first tranche at a price per share of approximately $9.2848. Sepracor has also agreed to purchase a second tranche of up to an additional $10 million of ACADIA common stock at a 25 percent premium to the trailing 30-day average closing sales price per share as of the one-year anniversary of the Effective Date, subject to customary closing conditions. These two stock purchases, in the aggregate, may not exceed 19.99 percent of ACADIAs outstanding common stock as of the second closing date, after giving effect to Sepracors purchases. In the event that ACADIA is required, pursuant to Nasdaq rules, to obtain, and fails to obtain, stockholder approval for the issuance of the full amount of shares, then the number of shares to be sold at the second closing would be decreased to a lesser amount. In that case, the lesser amount of shares to be sold to Sepracor in the second tranche would be the maximum number that could be sold without the required stockholder approval. If this lesser amount is sold to Sepracor, then Sepracor would also pay ACADIA 25 percent of the difference between the full amount of shares and the lesser number of shares actually purchased at the second closing multiplied by the trailing 30-day average closing sales price. The shares of ACADIA common stock to be issued to Sepracor pursuant to the purchase agreement were and will be issued pursuant to the exemption from the registration requirements of the Securities Act of 1933, as amended (the Securities Act), afforded by Section 4(2) of the Securities Act and Rule 506 of Regulation D thereunder, as a transaction to an accredited investor not involving a public offering. Sepracor represented its intention to acquire the securities for investment only and not with a view to or for sale in connection with any distribution thereof and an appropriate legend was affixed to the share certificate issued to Sepracor.
Under the terms of the stock purchase agreement, Sepracor has agreed to certain standstill provisions whereby it will refrain from acquiring or taking certain other actions with respect to ACADIA common stock. With respect to the shares of common stock purchased and to be purchased under the stock purchase agreement, Sepracor was granted certain piggyback and demand registration rights. These registration rights are set forth in a registration rights
agreement dated as of the Effective Date between Sepracor and ACADIA. A copy of the stock purchase agreement and registration rights agreement are filed as Exhibit 99.2 and Exhibit 99.3, respectively, to this current report, the contents of each of which are incorporated herein by reference.
A copy of the press release ACADIA issued with respect to the execution of the Collaboration Agreement is furnished with this current report as Exhibit 99.4.
Certain statements in this current report are forward-looking statements that involve risks and uncertainties. Such forward looking statements include statements with respect to the purchase of shares of ACADIA common stock, potential milestone and royalty payments under the collaboration, the research and development of drug candidates under the collaboration and the commercial launch of, and the safety, efficacy and potential benefits of, LUNESTA brand eszopiclone and any compounds discovered or developed under the collaboration. Actual events or results may differ materially from those projected in any forward-looking statements due to various factors, including the risks and uncertainties inherent in drug discovery, development and commercialization. Among the factors that could cause actual results to differ materially from those indicated by such forward-looking statements are: the ability of Sepracor and ACADIA to collaborate successfully; the ability to fund, and the results of, research, development and clinical trials; the timing and success of submission, acceptance, and approval of regulatory filings; the scope of Sepracors and ACADIAs patents and the patents of others; unexpected delays in commercial introduction of, and the commercial success of, LUNESTA; the ability of Sepracor and ACADIA to attract and retain qualified personnel; the ability of Sepracor and ACADIA to meet the closing conditions required for the consummation of the stock purchases; and certain other factors that are detailed in ACADIAs and Sepracors quarterly reports on Form 10-Q for the quarter ended September 30, 2004 filed with the Securities and Exchange Commission.
In addition, the statements in this current report represent ACADIAs expectations and beliefs as of the date of filing of this current report. ACADIA anticipates that subsequent events and developments may cause these expectations and beliefs to change. However, while ACADIA may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing ACADIAs expectations or beliefs as of any date subsequent to the filing date of this current report.
LUNESTA is a trademark of Sepracor Inc.